PMID- 11079615
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20171116
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 41
IP  - 5
DP  - 2000 Oct
TI  - In vitro activities of quinupristin/dalfopristin and eight other antimicrobial 
      agents against 360 clinical isolates from Korea.
PG  - 563-9
AB  - The emergence of multi-drug resistant gram-positive cocci such as 
      methicillin-resistant (MR) staphylococci, vancomycin-resistant (VR) enterococci, 
      and vancomycin-intermediate resistant S. aureus (VISA) has given new urgency to 
      the development of new antimicrobial agents. One of these is 
      quinupristin/dalfopristin (Q/D). We decided to determine the susceptibility of 
      gram-positive cocci isolated at two university hospitals in Seoul to Q/D and 
      compare the results with eight other antimicrobial agents. We investigated 120 
      isolates of S. aureus including 49 MRSAs and one VISA, 120 isolates of coagulase 
      negative staphylococci (CNS), 64 E. faecalis and 56 E. faecium, including seven 
      strains of VR E. faecium. Minimum inhibitory concentrations (MICs) and minimal 
      bactericidal concentrations (MBCs) for several antimicrobials, including 
      vancomycin and Q/D, were determined by broth microdilution. All S. aureus 
      including VISA were susceptible to Q/D. Q/D MIC90 for both 
      methicillin-susceptible S. aureus (MSSA) and MRSA was 0.25 g/mL. 49 (87.5%) of 56 
      E. faecium including six of seven VR E. faecium were susceptible to Q/D. E. 
      faecalis were not susceptible to Q/D (only 1.5% susceptible), but were inhibited 
      by ampicillin (94% susceptible) or vancomycin (95%). CNS was susceptible to Q/D 
      (96% susceptible) and vancomycin (100% susceptible). One of 38 staphylococci and 
      two of 17 E. faecium were tolerant to Q/D. In conclusion, Q/D showed excellent 
      activity against all species of gram-positive cocci including MRSA, VISA, and VR 
      E. faecium except E. faecalis, and may provide a valuable option for the 
      treatment of infections caused by these emerging nosocomial pathogens of 
      gram-positive cocci.
FAU - Hwang, S H
AU  - Hwang SH
AD  - Department of Clinical Pathology, University of Ulsan College of Medicine and 
      Asan Medical Center, Seoul, Korea.
FAU - Kim, M N
AU  - Kim MN
FAU - Pai, C H
AU  - Pai CH
FAU - Huh, D H
AU  - Huh DH
FAU - Shin, W S
AU  - Shin WS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Coagulase)
RN  - 11006-76-1 (Virginiamycin)
RN  - 23OW28RS7P (quinupristin)
RN  - R9M4FJE48E (dalfopristin)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Coagulase/analysis
MH  - Enterococcus faecalis/drug effects
MH  - Enterococcus faecium/drug effects
MH  - Humans
MH  - Korea
MH  - *Microbial Sensitivity Tests
MH  - Staphylococcus/drug effects/enzymology
MH  - Staphylococcus aureus/drug effects
MH  - Virginiamycin/*analogs & derivatives/*pharmacology
EDAT- 2000/11/18 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/18 11:00
PHST- 2000/11/18 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/18 11:00 [entrez]
AID - 10.3349/ymj.2000.41.5.563 [doi]
PST - ppublish
SO  - Yonsei Med J. 2000 Oct;41(5):563-9. doi: 10.3349/ymj.2000.41.5.563.